Nasdaq Announces Component Changes to Biotechnology Index

  
WASHINGTON, Jan. 22 /PRNewswire/ -- The Nasdaq Stock Market, Inc. today 
announced that effective with the market open on Tuesday, January 23, the 
components of the Nasdaq Biotechnology Index(R) (Nasdaq: IXBT) will change. 
A capitalization-weighted index representing the largest and most actively 
traded Nasdaq(R) biotechnology stocks, the Nasdaq Biotech Index includes 
companies primarily engaged in using biomedical research for the discovery or 
development of novel treatments and cures for human disease.  All securities 
in the Index must be listed on the Nasdaq National Market(R) and meet minimum 
requirements for price, market value, average daily share volume and seasoning 
as a public company.  In the future, the components will be reviewed 
semiannually and changes in the Index will be effective after the close of 
trading on the third Friday in May and November.  
Nasdaq is undertaking these changes to support a variety of new financial 
products.  Barclays Global Investors plans to launch an exchange traded fund 
(ETF) called the iShares Nasdaq Biotechnology Index Fund on February 2, 2001. 
The Index, as of January 23, will include the following 76 companies:  


      Abgenix, Inc. (Nasdaq: ABGX) 
    Affymetrix, Inc. (Nasdaq: AFFX) 
    Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) 
    Alkermes, Inc. (Nasdaq: ALKS) 
    Amgen Inc. (Nasdaq: AMGN) 
    Antigenics Inc. (Nasdaq: AGEN) 
    ArQule, Inc. (Nasdaq: ARQL) 
    Aurora Biosciences Corporation (Nasdaq: ABSC) 
    Avigen, Inc. (Nasdaq: AVGN) 
    Aviron (Nasdaq: AVIR) 
    Biochem Pharma Inc. (Nasdaq: BCHE) 
    Biogen, Inc. (Nasdaq: BGEN) 
    Celgene Corporation (Nasdaq: CELG) 
    Cell Genesys, Inc. (Nasdaq: CEGE) 
    Cell Therapeutics, Inc. (Nasdaq: CTIC) 
    Cephalon, Inc. (Nasdaq: CEPH) 
    Chiron Corporation (Nasdaq: CHIR) 
    COR Therapeutics, Inc. (Nasdaq: CORR) 
    Corixa Corporation (Nasdaq: CRXA) 
    Corvas International, Inc. (Nasdaq: CVAS) 
    Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) 
    CuraGen Corporation (Nasdaq: CRGN) 
    CV Therapeutics, Inc. (Nasdaq: CVTX) 
    Dendreon Corporation (Nasdaq: DNDN) 
    DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) 
    Emisphere Technologies, Inc. (Nasdaq: EMIS) 
    EntreMed, Inc. (Nasdaq: ENMD) 
    Enzon, Inc. (Nasdaq: ENZN) 
    Exelixis, Inc. (Nasdaq: EXEL) 
    Gene Logic Inc. (Nasdaq: GLGC) 
    Generex Biotechnology Corporation (Nasdaq: GNBT) 
    Genzyme General (Nasdaq: GENZ) 
    Geron Corporation (Nasdaq: GERN) 
    Gilead Sciences, Inc. (Nasdaq: GILD) 
    Guilford Pharmaceuticals Inc. (Nasdaq: GLFD) 
    Human Genome Sciences, Inc. (Nasdaq: HGSI) 
    ICOS Corporation (Nasdaq: ICOS) 
    IDEC Pharmaceuticals Corporation (Nasdaq: IDPH) 
    ImClone Systems Incorporated (Nasdaq: IMCL) 
    Immunex Corporation (Nasdaq: IMNX) 
    ImmunoGen, Inc. (Nasdaq: IMGN) 
    Incyte Genomics Inc. (Nasdaq: INCY) 
    Inhale Therapeutic Systems, Inc. (Nasdaq: INHL) 
    InterMune Pharmaceuticals, Inc. (Nasdaq: ITMN) 
    Isis Pharmaceuticals, Inc. (Nasdaq: ISIP) 
    Kos Pharmaceuticals, Inc. (Nasdaq: KOSP) 
    Lexicon Genetics Incorporated (Nasdaq: LEXG) 
    Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) 
    Luminex Corporation (Nasdaq: LMNX) 
    Matrix Pharmaceutical, Inc. (Nasdaq: MATX) 
    Medarex, Inc. (Nasdaq: MEDX) 
    MedImmune, Inc. (Nasdaq: MEDI) 
    Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) 
    Myriad Genetics, Inc. (Nasdaq: MYGN) 
    NeoPharm, Inc. (Nasdaq: NEOL) 
    Neurocrine Biosciences, Inc. (Nasdaq: NBIX) 
    NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) 
    ONYX Pharmaceuticals, Inc. (Nasdaq: ONXX) 
    OSI Pharmaceuticals Inc. (Nasdaq: OSIP) 
    PRAECIS PHARMACEUTICALS INC. (Nasdaq: PRCS) 
    Progenics Pharmaceuticals Inc. (Nasdaq: PGNX) 
    Protein Design Labs, Inc. (Nasdaq: PDLI) 
    QLT Inc. (Nasdaq: QLTI) 
    Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) 
    Ribozyme Pharmaceuticals, Inc. (Nasdaq: RZYM) 
    Sangamo BioSciences, Inc. (Nasdaq: SGMO) 
    Scios, Inc. (Nasdaq: SCIO) 
    SuperGen, Inc. (Nasdaq: SUPG) 
    Tanox, Inc. (Nasdaq: TNOX) 
    Transkaryotic Therapies, Inc. (Nasdaq: TKTX) 
    Trimeris, Inc. (Nasdaq: TRMS) 
    Tularik Inc. (Nasdaq: TLRK) 
    United Therapeutics Corporation (Nasdaq: UTHR) 
    Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) 
    Vical Incorporated (Nasdaq: VICL) 
    ViroPharma Incorporated (Nasdaq: VPHM) 


  The Nasdaq Biotechnology Index, launched in November 1993, rose 23 percent 
in 2000, although past performance is not necessarily indicative of future 
performance.  For more information about the Nasdaq Biotechnology Index, 
including eligibility criteria, visit:  http://www.nasdaq.com .  
  The Nasdaq Stock Market(R) lists nearly 5,000 companies, has the largest 
dollar volume of trades of any financial market, and trades more shares per 
day than any other U.S. market. Current market capitalization is $3.6 
trillion. Nasdaq is a subsidiary of the NASD, the largest securities-industry, 
self-regulatory organization in the United States. For more information about 
Nasdaq, visit the Nasdaq Web site at http://www.nasdaq.com or the Nasdaq 
Newsroom(SM) at http://www.nasdaqnews.com . 
  

SOURCE  The Nasdaq Stock Market  /CONTACT:  Judith Inosanto, 202-728-8243, or Kate Mitchel, 202-496-2627, 
both of the Nasdaq Stock Market/  


    /Web site:  http://www.nasdaqnews.com 
                http://www.nasdaq.com/ 


(IXBT)  
CO:  Nasdaq Stock Market; Nasdaq Biotechnology Index 
ST:  District of Columbia 
IN:  FIN BIO 
SU: 
-0- Jan/22/2001 22:42 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.